Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-Q for Primary Progressive Multiple Sclerosis
NCT06900192Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Mar 2025
- Primary completion
- Aug 2029
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of Orca-Q in primary progressive multiple sclerosis (PPMS), sponsored by Stanford University. Primary endpoint: Severe acute Graft-versus-Host-Disease-free survival at 365 days. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
Orca-Q
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT06900192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900192.